Association between implantable cardioverter-defibrillator therapy and different lead positions in patients with cardiac resynchronization therapy

被引:3
|
作者
Kronborg, Mads Brix [1 ]
Johansen, Jens Brock [2 ]
Haarbo, Jens [3 ]
Riahi, Sam [4 ]
Philbert, Berit Thornvig [5 ]
Jorgensen, Ole Dan [6 ]
Nielsen, Jens Cosedis [1 ]
机构
[1] Aarhus Univ Hosp, Dept Cardiol, Palle Juul Jensens Blvd 99, DK-8200 Aarhus N, Denmark
[2] Odense Univ Hosp, Dept Cardiol, Aarhus, Denmark
[3] Copenhagen Univ Hosp, Gentofte Hosp, Dept Cardiol, Copenhagen, Denmark
[4] Aalborg Univ Hosp, Dept Cardiol, Aalborg, Denmark
[5] Copenhagen Univ Hosp, Dept Cardiol, Rigshosp, Copenhagen, Denmark
[6] Odense Univ Hosp, Dept Heart Lung & Vasc Surg, Odense, Denmark
来源
EUROPACE | 2018年 / 20卷 / 09期
关键词
Cardiac resynchronization therapy; Lead position; Implantable cardioverter-defibrillator; Heart failure; Ventricular tachycardia; VENTRICULAR TACHYARRHYTHMIAS; MADIT-CRT; TRIAL; IMPACT; PLACEMENT; RISK;
D O I
10.1093/europace/eux296
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims To evaluate the impact of different right and left ventricular lead positions (RV-LP and LV-LP) on the risk of therapy for ventricular tachycardia/ventricular fibrillation in patients with a cardiac resynchronization therapy device (CRT-D). Methods and results We performed a large nationwide cohort study on patients in Denmark receiving a CRT-D device from 2008 to 2012 from the Danish Pacemaker and implantable cardioverter defibrillator (ICD) registry. Lead positions were registered during the implantation and categorized as anterior/lateral/posterior and basal/mid-ventricular/apical for the LV-LP, and as apical/non-apical for the RV-LP. Appropriate and inappropriate therapies were registered during follow-up via remote monitoring or at device interrogations. Time to event was summarized with Kaplan-Meier plots, and competed risk regression analysis was used to calculate adjusted hazard ratios (aHR) with 95% confidence intervals (CI). Following variables were included in the analysis: gender, age, heart failure aetiology, New York heart association class, left ventricular ejection fraction, QRS duration, indication (secondary or primary prophylactic), RV-LP, LV-LP, and antiarrhythmic therapy. We included 1643 patients [mean age 68 (+/- 10) years, 1343 (83%) men]. After a mean of 2.0 years, 322 (20%) patients received appropriate and 66 (4%) patients received inappropriate therapy. The aHR for appropriate therapy with a non-apical RV-LP was 0.70 95% CI (0.55-0.87, P = 0.002) as compared with an apical. We observed no significant association between appropriate therapy and LV-LP in left anterior oblique or right anterior oblique views or inappropriate therapy between any lead positions. Conclusion An apical RV-LP is associated with an increased risk of appropriate therapy for ventricular tachyarrhythmia in patients with a CRT-D device.
引用
收藏
页码:E133 / E139
页数:7
相关论文
共 50 条
  • [41] Cost-effectiveness of cardiac resynchronization therapy plus an implantable cardioverter-defibrillator in patients with heart failure: a systematic review
    Teimourizad, Abedin
    Rezapour, Aziz
    Sadeghian, Saeed
    Tajdini, Masih
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2021, 19 (01)
  • [42] Depression and anxiety in patients receiving an implantable cardioverter defibrillator with or without cardiac resynchronization therapy
    Sofia Plakoutsi
    Elizabeth Florou
    Dimitrios Sfairopoulos
    Petros Skapinakis
    Panagiotis Korantzopoulos
    Journal of Geriatric Cardiology, 2025, 22 (02) : 255 - 264
  • [43] Depression and anxiety in patients receiving an implantable cardioverter defibrillator with or without cardiac resynchronization therapy
    Plakoutsi, Sofia
    Florou, Elizabeth
    Sfairopoulos, Dimitrios
    Skapinakis, Petros
    Korantzopoulos, Panagiotis
    JOURNAL OF GERIATRIC CARDIOLOGY, 2025, 22 (02) : 255 - 264
  • [44] IMPACT OF IMPLANTABLE CARDIOVERTER DEFIBRILLATOR FOR PRIMARY PREVENTION IN PATIENTS UNDERGOING CARDIAC RESYNCHRONIZATION THERAPY
    Cabrera-Bueno, F.
    Molina-Mora, M. J.
    Pena-Hernandez, J.
    Leruite, I.
    Alzueta, J.
    Barrera-Cordero, A.
    De Teresa, E.
    JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2009, 20 : S92 - S93
  • [45] Cost-Effectiveness of Adding Cardiac Resynchronization Therapy to an Implantable Cardioverter-Defibrillator Among Patients With Mild Heart Failure
    Woo, Christopher Y.
    Strandberg, Erika J.
    Schmiegelow, Michelle D.
    Pitt, Allison L.
    Hlatky, Mark A.
    Owens, Douglas K.
    Goldhaber-Fiebert, Jeremy D.
    ANNALS OF INTERNAL MEDICINE, 2015, 163 (06) : 417 - +
  • [46] Cost-effectiveness of cardiac resynchronization therapy plus an implantable cardioverter-defibrillator in patients with heart failure: a systematic review
    Abedin Teimourizad
    Aziz Rezapour
    Saeed Sadeghian
    Masih Tajdini
    Cost Effectiveness and Resource Allocation, 19
  • [47] Frequency of Need for Antitachycardia or Antibradycardia Pacing or Cardiac Resynchronization Therapy in Patients With a Single-Chamber Implantable Cardioverter-Defibrillator
    Melles, Mireille C.
    Yap, Sing-Chien
    Bhagwandien, Rohit E.
    Sakhi, Rafi
    Szili-Torok, Tamas
    Theuns, Dominic A. M. J.
    AMERICAN JOURNAL OF CARDIOLOGY, 2018, 122 (12): : 2068 - 2074
  • [48] Implantable cardioverter-defibrillator therapy in clinical practice
    Cesario, DA
    Dec, GW
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (08) : 1507 - 1517
  • [49] Unresolved issues in implantable cardioverter-defibrillator therapy
    Mason, Pamela K.
    DiMarco, John P.
    CARDIOLOGY CLINICS, 2008, 26 (03) : 433 - +
  • [50] FUTURE EXPECTATIONS OF IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR THERAPY
    PRYSTOWSKY, EN
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 1995, 18 (03): : 609 - 615